Sarcopenia and dosimetric parameters in relation to treatment-related leukopenia and survival in anal cancer

Table 3 Logistic regressions of predictors for white blood cell grade ≥ 3 toxicity

Variable	WBC G3+ toxicity
	Univariate		Multivariate^a
	OR (95% CI)	P	OR (95% CI)	P
Female gender	2.7 (1.0–7.4)	0.049	3.2 (0.6–16.4)	0.17
Active smoking	0.8 (0.3–1.8)	0.58	.	.
Charlson comorbidity index ≥ 1	1.1 (0.5–2.4)	0.82	.	.
Immunosuppressive disorders	2.1 (0.6–7.4)	0.26		.
Sarcopenia	3.2 (1.4–7.4)	0.005	4.0 (1.6–9.8)	0.002
Age at diagnosis	1.02 (0.98–1.07)	0.40	.	.
Pretreatment leukocyte count	0.92 (0.82–1.02)	0.103	.	.
Pretreatment hemoglobin	0.99 (0.97–1.02)	0.52	.	.
PBM volume^b	0.86 (0.72–1.02)	0.08	0.96 (0.73–1.27)	0.79

CI confidence interval, OR odds ratio, PBM pelvic bone marrow, WBC white blood cell
^aPseudo R square for the multivariate model: Nagelkerke (0.17), Cox & Snell (0.13)
^bOR per 100 cc increase